DexCom, Inc. — Q1 2021 Form 10-Q
Reporting period: Three months ended March 31, 2021; unaudited consolidated results. Dexcom develops and sells continuous glucose monitoring (CGM) systems. Comparisons are with Q1 2020 unless stated otherwise. The company notes typical Q1 seasonality, including lower sales than the prior fourth quarter.
Financial performance
| Metric | Q1 2021 | Q1 2020 | Change |
|---|---|---|---|
| Revenue | $505.0 million | $405.1 million | Up 25% |
| Gross profit | $343.9 million | $256.5 million | Up 34% |
| Gross margin | 68.1% | 63.3% | Up 4.8 percentage points |
| Operating income | $45.9 million | $33.6 million | Up 37% |
| Net income | $40.3 million | $19.9 million | Up 103% |
| Diluted EPS | $0.41 | $0.21 | Up 95% |
| Operating cash flow | $27.8 million | $1.9 million | Up $25.9 million |
- Revenue growth was primarily driven by higher disposable sensor sales and worldwide customer-base growth; management cited pricing pressure related to channel strategy and product mix as offsets. Sensors and other represented about 84% of revenue, versus 80% a year earlier.
- Distributor-channel revenue increased to $390.7 million from $286.1 million; direct-channel revenue declined to $114.3 million from $119.0 million. U.S. revenue was $381.2 million (75% of total), and international revenue was $123.8 million (25%).
- Cost of sales rose 8%, slower than revenue growth. Management attributed improved gross profit and margin primarily to higher revenue and manufacturing efficiencies.
- Research and development expense increased 50% to $109.4 million, and selling, general and administrative expense increased 26% to $188.6 million. SG&A growth included higher advertising and marketing and payroll costs; R&D growth included higher payroll, consulting and clinical-trial costs.
- Interest expense increased to $24.8 million from $15.4 million, primarily due to the 2025 convertible notes issued in May 2020. The Q1 2021 income-tax benefit was $19.1 million, principally from excess tax benefits on employee share-based compensation; the company estimated a 21.4% full-year 2021 effective tax rate.
Liquidity, cash flow and debt
- Cash, cash equivalents and short-term marketable securities totaled $2.63 billion at March 31, 2021, down $75.1 million from year-end 2020. Cash and cash equivalents were $733.8 million; short-term marketable securities were $1.90 billion.
- Operating cash flow was $27.8 million. Investing activities used $112.2 million, including $99.7 million of capital expenditures; financing activities provided $0.8 million. Inventory increased to $289.7 million from $234.7 million.
- Senior convertible notes had $2.06 billion aggregate principal outstanding: $850.0 million due 2023 and $1.21 billion due 2025. Their balance-sheet liability component was $1.69 billion, excluding the separately recognized equity component. The company reported no revolving-credit borrowings and $193.6 million available under its $200 million facility; it was in compliance with covenants.
- Management expects existing cash and future operating cash flows to fund ongoing core business needs and believes available liquidity and the credit facility will meet anticipated requirements for at least the next 12 months.
Outlook, commentary and key risks
- No specific revenue, earnings or other numerical full-year guidance is provided in the supplied filing text. Management says results may fluctuate, cites normal Q1 seasonality, and expects continued investment in R&D and manufacturing capacity.
- COVID-19 effects remained uncertain. Dexcom reported supply-chain disruption affecting development of its next-generation CGM and identified potential impacts to manufacturing, distribution, clinical trials, sales cycles and customer insurance coverage.
- Material business risks include pricing and reimbursement pressure, dependence on third-party suppliers and manufacturing capacity, competition, product quality and regulatory approvals, and the ability to sustain channel relationships. Four significant distributors each generated at least 10% of Q1 revenue.
- Other disclosed risks include privacy and cybersecurity, international operations and currency exposure, and the substantial convertible-note obligations. Holders could have repurchase rights in specified circumstances; conversions may require cash or dilute shareholders, depending on settlement.
- The company reported ordinary-course legal claims but did not believe any currently pending proceeding was likely to have a material adverse effect. It cautioned that future proceedings could nonetheless have such an effect.
Important facts for investors to verify
- Whether sensor-volume growth continues and offsets pricing, reimbursement and product-mix pressure.
- Whether the shift toward distributors is sustainable, including dependence on the four major distributors cited in the filing.
- Whether manufacturing expansion, supplier availability and COVID-related disruptions affect product supply or next-generation product timing.
- Whether gross-margin improvement and operating cash generation persist as R&D, marketing and capital spending rise.
- The terms, conversion conditions and potential cash, dilution and refinancing implications of the 2023 and 2025 convertible notes.
- Whether future filings provide quantitative guidance or material updates on reimbursement, regulatory, litigation or cybersecurity matters.